Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK: Furosemide in Early Acute Kidney Injury
NCT00978354Phase 3Terminated
- Sponsor
- University of Alberta
- Start
- Sep 2009
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of furosemide in acute kidney injury (AKI) (2 arms), sponsored by University of Alberta. Primary endpoint: Progression in severity of kidney injury at 7 days. Started Sep 2009; status: terminated.
02
Drugs
furosemide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT00978354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00978354.